|
|
|
|
AnaMar news |
AMAP102, New Oral Cytokine Inhibitor to Treat Rheumatoid Arthritis - Phase 1 dosing completed , Results in Q1 |
| |
| The AMAP102 Phase 1 study, performed by Covance, was recently completed. Results are currently analysed and will be announced in Q1 2010. |
| |
|
|
|
|
|
|
|
